Novo Nordisk v. Cadila Healthcare: Ozempic Semaglutide Patents Dismissed Without Prejudice
Novo Nordisk filed suit in Delaware against generic challengers Cadila Healthcare and Zydus Pharmaceuticals over two patents protecting Ozempic semaglutide prefilled pen formulations. After 1,015 days of litigation, the case was dismissed without prejudice in December 2024 — leaving both parties’ legal positions formally open.
Novo Nordisk’s Ozempic patents tested — then dismissed by stipulation
On 4 March 2022, Novo Nordisk A/S filed suit in the United States District Court for the District of Delaware against Cadila Healthcare Ltd. and its US affiliate Zydus Pharmaceuticals (USA) Inc., asserting infringement of two patents — US10335462B2 and US9132239B2 — covering semaglutide subcutaneous injection formulations and prefilled pen delivery devices marketed as Ozempic. The action was a classic Hatch-Waxman ANDA infringement suit, triggered by the generic filers’ abbreviated new drug application targeting Novo Nordisk’s commercial products.
On 13 December 2024, Judge Colm F. Connolly entered a Stipulation and Order of Dismissal terminating all claims, counterclaims, and affirmative defenses without prejudice and without costs or attorneys’ fees to either party. The parties also expressly waived any right to appeal the dismissal order. The court retained jurisdiction to enforce the underlying Settlement Agreement, confirming that a private resolution — the terms of which are not public — preceded the dismissal.
The 1,015-day duration suggests negotiations were protracted, consistent with commercially sensitive ANDA settlements involving a blockbuster drug. A without-prejudice dismissal tied to a settlement agreement typically means the parties have agreed to defined commercial terms — often an authorised generic launch date or licensing arrangement — rather than litigating validity or infringement to judgment. The specific settlement terms remain confidential and cannot be confirmed from the public record.
Filing to Dismissed without Prejudice in 1015 days
1,015 days in litigation — nearly three years, consistent with contested Hatch-Waxman ANDA disputes
Without-prejudice dismissal: what the order means for both parties
Without prejudice means no final adjudication on the merits
A dismissal without prejudice does not resolve the underlying patent validity or infringement questions. Neither patent has been held valid, invalid, infringed, or not infringed by this order. The court’s jurisdiction was retained solely to enforce the accompanying Settlement Agreement. This leaves both patents legally intact and their enforceability against other ANDA filers unaffected by this proceeding.
No merits determinationPrivate settlement almost certainly underlies the dismissal
The court expressly retained jurisdiction to enforce a Settlement Agreement, confirming a private commercial resolution preceded the dismissal. Whether that agreement includes an authorised generic licence, a defined entry date for Zydus’s semaglutide product, royalty payments, or other commercial terms is not disclosed in the public record. The dismissal should not be read as a concession by either party on patent validity or infringement.
Settlement Agreement referencedNovo Nordisk’s Ozempic patents survive unchallenged on the merits
Because no court ruled on infringement or validity, US10335462B2 and US9132239B2 remain fully enforceable against other ANDA filers. Novo Nordisk retains the ability to assert both patents in future Hatch-Waxman actions. A negotiated resolution also removes the risk of an adverse invalidity or non-infringement ruling that could have benefited other generic challengers through collateral estoppel or persuasive precedent.
Patents intact and enforceableZydus preserves commercial optionality without admitting infringement
Zydus Pharmaceuticals and Cadila Healthcare avoided a potentially unfavourable trial outcome while securing whatever commercial terms are embedded in the private settlement. The without-prejudice structure means they have not formally conceded infringement. Their ability to launch a semaglutide product — and on what timeline — will be governed by the settlement’s confidential terms, which are not ascertainable from the public docket.
No infringement admissionFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novo Nordisk A/S | Individual | Global pharmaceutical innovator — holder of US10335462B2 and US9132239B2 covering Ozempic semaglutideSearch in Eureka ↗ |
| Co-Plaintiff | Novo Nordisk A/S | Individual | Search in Eureka ↗ |
| Defendant | Cadila Healthcare, Ltd. | Company | Indian generic manufacturer Cadila Healthcare and its US subsidiary Zydus Pharmaceuticals seeking ANDA approvalSearch in Eureka ↗ |
| Co-Defendant | Zydus Pharmaceuticals (USA), Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Cadila Healthcare, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Novo Nordisk A/SSearch in Eureka ↗ |
| Defendant counsel | Alexis Stombaugh | Attorney | Counsel for Cadila Healthcare, Ltd.Search in Eureka ↗ |
| Defendant counsel | August M. Melcher | Attorney | Counsel for Cadila Healthcare, Ltd.Search in Eureka ↗ |
| Defendant counsel | Carolyn A. Blessing | Attorney | Counsel for Cadila Healthcare, Ltd.Search in Eureka ↗ |
| Defendant counsel | David B. Abramowitz | Attorney | Counsel for Cadila Healthcare, Ltd.Search in Eureka ↗ |
| Defendant counsel | Jacob C. Britz | Attorney | Counsel for Cadila Healthcare, Ltd.Search in Eureka ↗ |
| Defendant counsel | Michael J. Gaertner | Attorney | Counsel for Cadila Healthcare, Ltd.Search in Eureka ↗ |
| Defendant counsel | Pilar Gabrielle Kraman | Attorney | Counsel for Cadila Healthcare, Ltd.Search in Eureka ↗ |
| Defendant law firm | Young Conaway Stargatt & Taylor, LLP | Law Firm | Representing Cadila Healthcare, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The December 2024 order is a stipulated dismissal rather than a judicial merits ruling. Its key operative effect is twofold: all claims and counterclaims are extinguished without prejudice — meaning no res judicata bar attaches — while the court retains supervisory jurisdiction over the private Settlement Agreement. The express appeal waiver by both parties closes the appellate path but does not resolve patent validity or infringement. Neither US10335462B2 nor US9132239B2 has been adjudicated, leaving their enforceability intact.
US10335462B2 & US9132239B2 — Semaglutide injection formulation and delivery
US10335462B2 derives from US application 15/656042 and protects semaglutide subcutaneous injection formulations, including the specific concentrations (1.34 mg/ml) used in Ozempic prefilled pens at 2 mg/1.5 ml and 4 mg/3 ml doses. US9132239B2 derives from US application 13/124995 — an earlier application reflecting foundational work on the GLP-1 analogue pharmaceutical compositions. Together, the two patents span both the compound formulation and device-specific delivery aspects of the Ozempic commercial product.
Ozempic has become one of the highest-revenue pharmaceutical products globally, making its patent estate a high-stakes target for generic challengers. The two asserted patents represent distinct layers of protection — an earlier composition-focused patent and a later formulation-specific patent covering commercial dosing presentations. Any ANDA filer seeking to launch a semaglutide subcutaneous injection product in the United States must contend with both patents, and the absence of any invalidity ruling in this case means neither has been weakened by litigation.
Should your semaglutide pipeline trigger an FTO against US10335462B2?
Any company developing a GLP-1 receptor agonist subcutaneous injection — particularly a semaglutide biosimilar, follow-on formulation, or prefilled pen delivery system — should conduct a rigorous freedom-to-operate analysis against both US10335462B2 and US9132239B2 before advancing to ANDA or NDA filing. The Delaware dismissal did not narrow the claims, construe claim language, or create any estoppel that could assist a future challenger. Both patents enter the next enforcement action with their full original scope.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map the independent and dependent claims of US10335462B2 and US9132239B2 against proposed formulation parameters, concentration ranges, and device configurations. Eureka surfaces prosecution history, related family members, and comparable ANDA litigation outcomes across Novo Nordisk’s broader semaglutide portfolio — enabling data-driven decisions on design-around opportunities or IPR petition viability before a costly ANDA suit is triggered.
Run a freedom-to-operate analysis on US10335462B2 to assess your product’s exposure
Run FTO in Eureka →Similar semaglutide and GLP-1 ANDA patent cases in Delaware
Cases involving Hatch-Waxman ANDA challenges to GLP-1 and semaglutide patents litigated in the District of Delaware, including related Novo Nordisk enforcement actions.
What this case signals for the semaglutide and GLP-1 IP landscape
The settlement of this Ozempic ANDA suit reflects broader dynamics in GLP-1 receptor agonist patent enforcement as multiple generics queue for market entry.
Without-prejudice dismissals preserve Novo Nordisk’s enforcement posture
Because the court made no validity or infringement ruling, Novo Nordisk can assert US10335462B2 and US9132239B2 against every subsequent ANDA filer on a clean slate. IP teams monitoring the semaglutide patent estate should note that these patents have not been tested to judgment and their scope remains fully untested by litigation.
Settlement timing suggests commercial negotiation outweighed litigation risk
A 1,015-day ANDA dispute ending in stipulated dismissal — without any published claim construction, summary judgment ruling, or trial — suggests both sides prioritised certainty over a judicial outcome. For other generics watching this space, the absence of any merits ruling removes a potential invalidity precedent that could have lowered barriers to entry.
A/S v Cadila — key questions answered
Novo Nordisk asserted two patents: US10335462B2 (application 15/656042) and US9132239B2 (application 13/124995), both covering semaglutide subcutaneous injection formulations and delivery aspects of Ozempic prefilled pen products at concentrations of 1.34 mg/ml.
A without-prejudice dismissal means no court ruled on validity or infringement. US10335462B2 and US9132239B2 remain fully enforceable. Novo Nordisk retains the right to assert both patents against other ANDA filers, and Cadila/Zydus have not formally conceded infringement. The settlement terms governing any commercial resolution are confidential.
The December 2024 dismissal order references an underlying Settlement Agreement and retains court jurisdiction to enforce it, confirming a private settlement was reached. The specific terms — including any authorised generic entry date, licensing arrangements, or payments — are not disclosed in the public court record and cannot be confirmed.
Delaware District Court is the standard venue for Hatch-Waxman ANDA patent disputes because ANDA filers and branded companies commonly consent to jurisdiction there. Judge Connolly’s court is among the most experienced in the country for pharmaceutical patent litigation, making Delaware the typical first-choice forum for innovator enforcement actions.
No. Because the dismissal was without prejudice and no validity or infringement ruling was entered, other ANDA filers receive no legal benefit — no invalidity finding, no claim construction, and no estoppel. Each subsequent challenger must independently establish a case against US10335462B2 and US9132239B2, facing the full original patent claims without any weakening from this proceeding.
PatSnap Eureka searches patents and litigation data to answer instantly.